Clinical Trials Directory

Trials / Completed

CompletedNCT04293029

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

Conditions

Interventions

TypeNameDescription
DRUGSHR0302SHR0302

Timeline

Start date
2020-05-20
Primary completion
2020-12-27
Completion
2020-12-30
First posted
2020-03-03
Last updated
2021-10-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04293029. Inclusion in this directory is not an endorsement.